PT  - JOURNAL ARTICLE
AU  - Sourij, H.
AU  - Aziz, F.
AU  - Bräuer, A.
AU  - Ciardi, C.
AU  - Clodi, M.
AU  - Fasching, P.
AU  - Karolyi, M.
AU  - Kautzky-Willer, A.
AU  - Klammer, C.
AU  - Malle, O.
AU  - Oulhaj, A.
AU  - Pawelka, E.
AU  - Peric, S.
AU  - Ress, C.
AU  - Sourij, C.
AU  - Stechemesser, L.
AU  - Stingl, H.
AU  - Stulnig, TM.
AU  - Tripolt, N.
AU  - Wagner, M.
AU  - Wolf, P.
AU  - Zitterl, A.
AU  - Kaser, S.
AU  - ,
TI  - Covid-19 fatality prediction in people with diabetes and prediabetes using a simple score at hospital admission
AID  - 10.1101/2020.11.02.20224311
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.02.20224311
4099  - http://medrxiv.org/content/early/2020/11/04/2020.11.02.20224311.short
4100  - http://medrxiv.org/content/early/2020/11/04/2020.11.02.20224311.full
AB  - AIM We assessed predictors of in-hospital mortality in people with prediabetes and diabetes hospitalized for COVID-19 infection and developed a risk score for identifying those at the highest risk of a fatal outcome.MATERIALS AND METHODS A combined prospective and retrospective multicenter cohort study was conducted in 10 sites in Austria on 247 people with diabetes or newly diagnosed prediabetes, who were hospitalised for COVID-19. The primary outcome was in-hospital mortality and predictor variables at the time of admission included clinical data, comorbidities of diabetes or laboratory data. Logistic regression analyses were performed to identify significant predictors and develop a risk score for in-hospital mortality.RESULTS The mean age of people hospitalized (n=238) for COVID-19 was 71.1 ± 12.9 years, 63.6% were males, 75.6% had type 2 diabetes, 4.6% had type 1 diabetes, and 19.8% had prediabetes. The mean duration of hospital stay was 18 ± 16 days, 23.9% required ventilation therapy, and 24.4% died in the hospital. Mortality rate in people with diabetes was numerically higher (26.7%) as compared to those with prediabetes (14.9%) but without statistical significance (p=0.128). A score including age, arterial occlusive disease, CRP, eGFR and AST levels at admission predicted in-hospital mortality with a C-statistics of 0.889 (95%CI: 0.837 – 0.941) and calibration of 1.000 (p=0.909).CONCLUSIONS The in-hospital mortality for COVID-19 was high in people with diabetes and not significantly different to the risk in people with prediabetes. A risk score using five routinely available patient parameters demonstrated excellent predictive performance for assessing in-hospital mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by unrestricted research grants to the Austrian Diabetes Association from NovoNordisk, Novartis, Sanofi, AstraZeneca and Boehringer Ingelheim. The study funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nationwide ethics approval was obtained from the Ethics Committee of the Medical University of Graz, Austria (EK 32-355 ex 19/20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Austrian Diabetes Association has full access to the dataset and access can be granted upon request.